Léa Wenger
Cyclana Bio, CEO & Co-founder
I am CEO and Co-Founder of Cyclana Bio with a background in Veterinary Medicine and a PhD in Neuroscience from Cambridge University. After I was diagnosed with endometriosis myself, I started iterating jointly with my cofounder Prof. Kevin Chalut on the idea of how to apply our learnings to women's health. We are strongly driven by the desire to close the gender health gap through creating a flagship program for how to solve disease at the tissue level. Cyclana Bio has raised £5 million ($6.7 million) in 2025 to advance its drug discovery for endometriosis. The pre-seed funding round was co-led by NfX and Eka VC, with investors including Cocoa VC, Wilbe, and Angel investors.
EXPs by Léa Wenger
Studying women’s health is not just about closing a gender health gap ; it is an opportunity to use new information to perform better science more broadly.
Endometriosis is a hidden disease affecting women with an invasive nature similar only to cancer.
Having a win in endometriosis could massively propel our understanding in women's health.
Cyclana Bio is an innovative company building the whole discovery pipeline for endometriosis until the development of therapies. Its unique tissue biology approach should be crucial to cure chronic inflammatory diseases.